Companies /Healthcare

Cue Biopharma

NASDAQ: CUE Biotechnology
$4.15
▼ $0.35 (−7.78%) today
Markets closed · 12:05pm ET

CUE at a Glance

Valuation
Market cap
$34.7M
Profitability
Revenue (TTM)
$35.6M
EPS (TTM)
$-27.80
Price
52-week range
$3 – $46
Street target
$68.67

Headquartered in Boston, MA Fiscal year ends December NASDAQ: CUE cuebiopharma.com

About Cue Biopharma

Cue Biopharma is a clinical-stage biopharmaceutical company developing therapies intended to deliver durable, potentially disease-modifying benefits in immune-mediated diseases, including allergic and autoimmune conditions.

Its lead asset, CUE-221 (also known as Ascendant-221 / UB-221), is in-licensed from Ascendant. It is a humanized anti-IgE IgG1 monoclonal antibody with a dual mechanism of action: it neutralizes free IgE and preserves IgE binding to CD23 on B cells to suppress new IgE synthesis. CUE-221 has completed a positive Phase 2 study in chronic spontaneous urticaria (CSU), and its IND for food allergy has been cleared by the FDA.

Its lead autoimmune candidate, CUE-401, is an engineered bispecific fusion protein of attenuated IL-2 and TGF-β. It is designed to drive regulatory T cell (Treg)-mediated immune tolerance and is now in a first-in-human Phase 1 trial.

Cue also developed the Immuno-STAT platform, which selectively targets disease-specific T cells in vivo.

The company generates collaboration revenue from partnerships, including a Collaboration and License Agreement with Boehringer Ingelheim, and has a license agreement with ImmunoScape that provides milestone-style payments. Updated

Latest Activity

CUECue Biopharma
Q3 2026
EPS
-$4.74
est -$2.24-111.3%
Revenue
$132K
est $1M-87.2%

The loss came in at more than double consensus, missing expectations on non-cash charges including the Ascendant top-up share obligation revaluation and performance equity grants from the Q2 strategic overhaul. With collaboration revenue nearly gone as Boehringer Ingelheim activity winds down, $57.9 million in cash has to carry CUE-221 into food allergy trials after FDA IND clearance.

Quarterly EPS — reported vs estimate

CUE Coverage

Frequently Asked Questions

What does Cue Biopharma do?

Cue Biopharma is a clinical-stage biopharmaceutical company developing therapies intended to deliver durable, potentially disease-modifying benefits in immune-mediated diseases, including allergic and autoimmune conditions. Its lead asset, CUE-221 (also known as Ascendant-221 / UB-221), is in-licensed from Ascendant.

What is the CUE stock price target?

The Wall Street consensus 12-month price target for CUE is $68.67.